HL-400 vs Parunoflast

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: NLRP3 · full Parkinson's Disease pipeline

HL-400

Developed by Hangzhou Highlightll Pharmaceutical

Phase 1 in Parkinson's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Parunoflast

Developed by Eli Lilly and partners

Phase 2 in Parkinson's Diseasesmall molecule
Weak signal

NCT06556173 · Phase 2 · completed

The study was a small, single-arm, open-label trial with no placebo or active comparator and no randomization. Its primary endpoint was adverse-event incidence. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Adverse Event (AE) / Serious Adverse Event (SAE) Incidence Rate and Severity through study completion (Day 1 of treatment period through study completion, up to 6 weeks): AE/SAE incidence through study completion, VTX3232 40mg once daily x28 days (n=10, open-label, no placebo arm): 0 drug-related TEAEs; 0 serious adverse events; all reported AEs mild-to-moderate and unrelated to treatment (not_applicable)

Result source: NCT06556173

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHL-400Parunoflast
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

HL-400
—Not reported
Parunoflast
—Not reported

ON time without troublesome dyskinesia, change

HL-400
—Not reported
Parunoflast
—Not reported

UPDRS Part III, change

HL-400
—Not reported
Parunoflast
—Not reported

MDS-UPDRS Part II, change

HL-400
—Not reported
Parunoflast
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HL-400: no structured comparison results are available for Parkinson's Disease.

Parunoflast: no structured comparison results are available for Parkinson's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HL-400's landscape · Parunoflast's landscape